Literature DB >> 10543744

Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.

P Marichal1, J Gorrens, L Laurijssens, K Vermuyten, C Van Hove, L Le Jeune, P Verhasselt, D Sanglard, M Borgers, F C Ramaekers, F Odds, H Vanden Bossche.   

Abstract

The effects of itraconazole on ergosterol biosynthesis were investigated in a series of 16 matched clinical Candida albicans isolates which had been previously analyzed for mechanisms of resistance to azoles (D. Sanglard, K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother., 39:2378-2386, 1995). Under control conditions, all isolates contained ergosterol as the predominant sterol, except two strains (C48 and C56). In isolates C48 and C56, both less susceptible to azoles than their parent, C43, substantial concentrations (20 to 30%) of 14alpha-methyl-ergosta-8,24(28)-diene-3beta,6alpha-dio l (3, 6-diol) were found. Itraconazole treatment of C43 resulted in a dose-dependent inhibition of ergosterol biosynthesis (50% inhibitory concentration, 2 nM) and accumulation of 3,6-diol (up to 60% of the total sterols) together with eburicol, lanosterol, obtusifoliol, 14alpha-methyl-ergosta-5,7,22,24(28)-tetraene-3betaol, and 14alpha-methyl-fecosterol. In strains C48 and C56, no further increase of 3,6-diol was observed after exposure to itraconazole. Ergosterol synthesis was less sensitive to itraconazole inhibition, as was expected for these azole-resistant isolates which overexpress ATP-binding cassette transporter genes CDR1 and CDR2. In addition to 3,6-diol, substantial amounts of obtusifolione were found after exposure to itraconazole. This toxic 3-ketosteroid was demonstrated previously to accumulate after itraconazole treatment in Cryptococcus neoformans and Histoplasma capsulatum but has not been reported in Candida isolates. Accumulation of obtusifolione correlated with nearly complete growth inhibition in these azole-resistant strains compared to that found in the susceptible parent strain, although the onset of growth inhibition only occurred at higher concentrations of itraconazole. ERG25 and ERG26 are the only genes assigned to the 4-demethylation process, of which the 3-ketoreductase is part. To verify whether mutations in these ERG25 genes contributed to obtusifolione accumulation, their nucleotide sequences were determined in all three related isolates. No mutations in ERG25 alleles of isolates C48 and C56 were found, suggesting that this gene is not involved in obtusifolione accumulation. The molecular basis for the accumulation of this sterol in these two strains remains to be established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543744      PMCID: PMC89540     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans.

Authors:  H van den Bossche; G Willemsens; W Cools; W F Lauwers; L Le Jeune
Journal:  Chem Biol Interact       Date:  1978-04       Impact factor: 5.192

Review 5.  Molecular mechanisms of azole resistance in fungi.

Authors:  T Joseph-Horne; D W Hollomon
Journal:  FEMS Microbiol Lett       Date:  1997-04-15       Impact factor: 2.742

6.  Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

Authors:  T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 7.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

Review 8.  Antifungal drug resistance in pathogenic fungi.

Authors:  H Vanden Bossche; F Dromer; I Improvisi; M Lozano-Chiu; J H Rex; D Sanglard
Journal:  Med Mycol       Date:  1998       Impact factor: 4.076

9.  Resistance to imidazoles and triazoles in Saccharomyces cerevisiae as a new dominant marker.

Authors:  F Doignon; M Aigle; P Ribereau-Gayon
Journal:  Plasmid       Date:  1993-11       Impact factor: 3.466

10.  Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; D E Kelly
Journal:  Biochem Biophys Res Commun       Date:  1995-02-27       Impact factor: 3.575

View more
  14 in total

1.  Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.

Authors:  M D De Backer; T Ilyina; X J Ma; S Vandoninck; W H Luyten; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

Review 3.  [Local combination therapy of inflammatory dermatomycosis: A review of recommendations in national and international guidelines].

Authors:  V A Czaika; T Zuberbier
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

Review 4.  Resistance to antifungals that target CYP51.

Authors:  Josie E Parker; Andrew G S Warrilow; Claire L Price; Jonathan G L Mullins; Diane E Kelly; Steven L Kelly
Journal:  J Chem Biol       Date:  2014-08-27

5.  Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Authors:  Hanan K Munayyer; Paul A Mann; Andrew S Chau; Taisa Yarosh-Tomaine; Jonathan R Greene; Roberta S Hare; Larry Heimark; Robert E Palermo; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Authors:  Hugo Vanden Bossche; Jannie Ausma; Hilde Bohets; Karen Vermuyten; Gustaaf Willemsens; Patrick Marichal; Lieven Meerpoel; Frank Odds; Marcel Borgers
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.

Authors:  J E Parker; M Merkamm; N J Manning; D Pompon; S L Kelly; D E Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

8.  Exploration of whole-genome responses of the human AIDS-associated yeast pathogen Cryptococcus neoformans var grubii: nitric oxide stress and body temperature.

Authors:  Eric D Chow; Oliver W Liu; Sean O'Brien; Hiten D Madhani
Journal:  Curr Genet       Date:  2007-07-28       Impact factor: 3.886

9.  Δ(24)-Sterol Methyltransferase Plays an Important Role in the Growth and Development of Sporothrix schenckii and Sporothrix brasiliensis.

Authors:  Luana P Borba-Santos; Gonzalo Visbal; Thalita Gagini; Anderson M Rodrigues; Zoilo P de Camargo; Leila M Lopes-Bezerra; Kelly Ishida; Wanderley de Souza; Sonia Rozental
Journal:  Front Microbiol       Date:  2016-03-11       Impact factor: 5.640

10.  Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi.

Authors:  Mike Bromley; Anna Johns; Emma Davies; Marcin Fraczek; Jane Mabey Gilsenan; Natalya Kurbatova; Maria Keays; Misha Kapushesky; Marta Gut; Ivo Gut; David W Denning; Paul Bowyer
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.